Why did Core Laboratories (CLB) stock move recently?

On 8/4/2026, Core Laboratories moved +4.8% — Core Laboratories shares rose after the announcement that CEO Lawrence Bruno bought 5,000 shares. This is MarketChacha's decoded reason from filings and credible news; it is education, not buy/sell advice.

Is Core Laboratories (CLB) overvalued or fairly valued?

MarketChacha shows Core Laboratories's valuation in context — a trailing P/E of about 16.0, a forward P/E of about 14.6, a price-to-book of about 1.7 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Core Laboratories's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.21×) from reported figures — education, not a rating.

What is Core Laboratories's revenue?

Core Laboratories reported revenue of $526.5M for FY2025, with net profit of $29.7M, per official filings.

What is the share price of Core Laboratories (CLB)?

Core Laboratories last traded at $10.07 (-0.8% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Core Laboratories

CLB · NYSE · Energy · United States

Snapshot

TickerCLB

ExchangeNYSE

SectorEnergy

IndustryOil & Gas Equipment & Services

CountryUnited States

Employees3,300

HeadquartersHouston, United States

Websitewww.corelab.com

Filings tracked14

About Core Laboratories

Core Laboratories Inc. provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and natural gas from its clients' reservoirs. It offers laboratory-based analytical and field services to characterize properties of crude oil and oil delivered products; and proprietary and joint industry studies, as well as services that support carbon capture, utilization and storage, geothermal projects, and the evaluation and appraisal of mining activities. The Production Enhancement segment provides services and products relating to reservoir well completions, perforations, stimulations, production, and well abandonment. It offers integrated diagnostic services to evaluate and monitor the effectiveness of well completions and to develop solutions to improve the effectiveness of enhanced oil recovery projects. The company markets and sells its products through a combination of sales representatives, technical seminars, trade shows, and print advertising, as well as through distributors. Core Laboratories Inc. was founded in 1936 and is based in Houston, Texas.

Who owns it

Insiders1.4%
Institutions98.6%
Public & other0.0%

258 institutional holders

Ownership breakdown from public market data.

Top holders

Ariel Investments, LLC30.67%
Blackrock Inc.16.26%
Disciplined Growth Investors, Inc.6.63%
Earnest Partners LLC6.41%
State Street Corporation4.74%
Vanguard Capital Management LLC3.47%
Dimensional Fund Advisors LP3.37%
Schroder Investment Management Group3.36%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.21×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend7.2% → 5.6%

Margin has held broadly steady over the period — stable profitability.

Growth qualityrev 2% · PAT -10%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $133.3M · EPS 0.17

Est. earnings growth -19.0%

Next fiscal year

Rev $524.8M · EPS 0.69

Est. earnings growth +36.2%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$526.5M

Net margin

5.6%

ROE

11.2%

Revenue CAGR (2y)

+1.6%

Profit CAGR (2y)

-10.1%

EPS (FY2025)

0.63

Net profit (FY2025)

$29.7M

Ask MarketChacha about CLB

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Why it moved

Aug 4, 2026
Core Laboratories shares rose after the announcement that CEO Lawrence Bruno bought 5,000 shares.
source 1 ↗· confidence: medium
Jul 28, 2026
No company-specific news, filing, or earnings release today (Q2 results scheduled after close July 29); the decline appears to reflect broader market or sector movement ahead of earnings.
· confidence: low
Jul 27, 2026
No specific company catalyst identified for the decline; CLB moved lower with broader market/sector sentiment ahead of its Q2 earnings release scheduled for July 29.
· confidence: low
Jul 22, 2026
No clear company-specific catalyst identified; the move appears to lack support from recent filings or today's news coverage.
· confidence: low

Daily moves with the verified reason behind them. Education only — not investment advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$526.5M	$29.7M	0.63	5.6%	11.2%
FY2024	$523.8M	$31.4M	0.66	6.0%	12.7%
FY2023	$509.8M	$36.7M	0.77	7.2%	16.3%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$124.6M	$6.0M	0.13	4.8%
2026Q1	$121.8M	$-789,000	-0.02	-0.6%
2025Q3	$134.5M	$14.2M	0.30	10.6%
2025Q2	$130.2M	$10.6M	0.22	8.2%
2025Q1	$123.6M	$-154,000	0.00	-0.1%
2024Q3	$134.4M	$11.7M	0.25	8.7%
2024Q2	$130.6M	$9.0M	0.19	6.9%
2024Q1	$129.6M	$3.2M	0.07	2.5%
2023Q3	$125.3M	$9.3M	0.19	7.4%
2023Q2	$127.9M	$22.8M	0.48	17.9%
2023Q1	$128.4M	$2.4M	0.05	1.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Executive/director change, Exhibits
SEC8/25/2026material
10-Q filing
SEC7/30/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC7/29/2026material
8-K — Shareholder vote results
SEC5/13/2026material
10-Q filing
SEC5/1/2026
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC4/29/2026material
10-K filing
SEC3/23/2026
8-K — Reg FD disclosure, Exhibits
SEC3/23/2026material
8-K/A — Results of operations
SEC3/17/2026
8-K — Bylaw/charter change, Exhibits
SEC3/5/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC2/4/2026material

2025

10-Q filing
SEC10/23/2025
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC10/22/2025material
10-Q filing
SEC7/25/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.